Personalising care: using infliximab drug trough and anti-drug antibody levels improves clinical treatment decisions and is a cost-effective strategy in spondyloarthritis

by Sayam Dubash, Domini Bryer, John Fitton, Andrew Barr, Claire Vandevelde, Helena Marzo-Ortega, Jane Freeston

Published in Clinical medicine (London) by Royal College of Physicians.

2019 Volume 19, Issue Suppl 2, p106-107

application/pdf 67.0 kB
file_imo35bdervaphpp2ivmoxx7vce www.rcpjournals.org (web)
web.archive.org (webarchive)

Preserved and Accessible

Type article-journal
Stage

published

Year 2019
Language en ^?

DOI 10.7861/clinmedicine.19-2-s106

Container Metadata
Not in DOAJ
In Keepers Registry
ISSN-L: 1470-2118

Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)

Cite This

BibTeX
CSL-JSON
MLA
Harvard

Lookup Links

oaDOI/unpaywall (OA fulltext)
Crossref Metadata (via API)
Worldcat
SHERPA/RoMEO (journal policies)
wikidata.org
CORE.ac.uk
Semantic Scholar
Google Scholar

Catalog Record
Revision: 05be33b1-e9c2-45a3-acad-0dee8da9b6bd
API URL: JSON

Personalising care: using infliximab drug trough and anti-drug antibody levels improves clinical treatment decisions and is a cost-effective strategy in spondyloarthritis release_afzlilennvc5ffaufsgqjzekqm